A single-centre, prospective, longitudinal study to evaluate the clinical response and association of drug exposure with toxicity in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib

Trial Profile

A single-centre, prospective, longitudinal study to evaluate the clinical response and association of drug exposure with toxicity in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top